Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and PEGPH20 in Metastatic Pancreatic Cancer
NCT04058964Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2020
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegvorhyaluronidase alfa in pancreatic adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression Free Survival at 1 year. Planned start Feb 2020; status: withdrawn.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04058964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058964.